CeriBell Financial Ratios
NASDAQ: CBLLHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CeriBell ratio analysis
CeriBell earned a net margin of -60.0% in FY 2025, up from -61.8% a year earlier. Gross margin was 87.9% compared with a median of 85.6% over the prior 2 years. Return on equity reached -34.4%, meaning CeriBell generated -0.34 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.13 versus 0.10 the year before, and the current ratio was 9.73. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
CeriBell financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Price / sales | 8.74 | 4.44 | — |
| Price / book | 5.01 | 1.52 | — |
| Gross margin | 87.9% | 86.7% | 84.4% |
| Operating margin | -65.6% | -60.7% | -66.4% |
| Net margin | -60.0% | -61.8% | -65.1% |
| Free cash flow margin | -46.7% | -55.6% | -66.6% |
| Return on equity (ROE) | -34.4% | -21.2% | — |
| Return on assets (ROA) | -27.3% | -17.9% | -50.0% |
| Debt / equity | 0.13 | 0.10 | — |
| Current ratio | 9.73 | 16.73 | 2.41 |
| Revenue growth | 36.1% | 44.7% | — |